In a report released today, Sami Corwin from William Blair maintained a Buy rating on Cabaletta Bio. The company’s shares closed yesterday at $2.85.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ultragenyx Pharmaceutical, and PTC Therapeutics. According to TipRanks, Corwin has an average return of 28.8% and a 58.82% success rate on recommended stocks.
Cabaletta Bio has an analyst consensus of Strong Buy, with a price target consensus of $12.00.
The company has a one-year high of $5.46 and a one-year low of $0.99. Currently, Cabaletta Bio has an average volume of 1.67M.
Read More on CABA:
Disclaimer & DisclosureReport an Issue
- Cabaletta Bio jumps 30% to $3.13 after pemphigus vulgaris data
- Cabaletta Bio Presents Promising RESET-PV Trial Data
- Cabaletta Bio presents initial dose data from RESET-PV trial of rese-cel
- Cabaletta Bio: Buy Rating Backed by Promising Trial Data and Strategic Financial Outlook
- Cabaletta Bio Updates on Rese-cel Therapy Progress
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
